The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Joint Authors
Mu, Yi-Ming
Wang, Jie
An, Ping
Jin, Xinye
Yu, Songyan
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-28
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
In patients with type 2 diabetes mellitus (T2DM) and poor glycemic control receiving metformin (MET), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended as the adjunctive therapy.
However, there are only a few studies involving the comparative effects of exenatide twice a day (EXBID) and exenatide once weekly (EXQW) on HOMA-β.
This meta assessed the comparative effects of EXQW and EXBID on HOMA-β among T2DM patients.
Materials and Methods.
PubMed, Cochrane Library, and Embase databases were searched to collect randomized controlled trials (RCTs).
Network meta-analysis was performed, and network diagrams were constructed to evaluate the effects.
The primary outcome is HOMA-β, and the secondary outcomes are fasting blood glycose (FBG), glycated hemoglobin (HbA1c), and weight loss.
Results.
A total of 8 studies with 3506 subjects were included.
Compared with other antidiabetic agents, EXQW has a greater improvement in HOMA-β than EXBID (weight mean difference WMD=‐0.46, 95% confidence interval (CI) [-0.64, -0.28], P=0.001).
The effect of EXQW on HbA1c is superior to that of sitagliptin (SITA) (WMD=0.51, 95% CI [0.03, 0.99], P=0.037).
The significant reduction of weight was detected for EXBID in comparison with EXQW (WMD=‐0.73, 95% CI [-1.13, -0.33], P=0.001), and no significant difference was found between EXQW and MET.
Conclusions.
EXQW shows a greater improvement in HOMA-β than EXBID.
Moreover, the efficacy of EXQW on glycemic control is similar to other antidiabetic agents including EXBID.
It is an advisable treatment for diabetic patients to improve HOMA-β and has an advantage of fewer number of injections compared with EXBID, to increase patients’ adherence and quality of life.
American Psychological Association (APA)
Wang, Jie& Jin, Xinye& An, Ping& Yu, Songyan& Mu, Yi-Ming. 2019. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Journal of Diabetes Research،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1173254
Modern Language Association (MLA)
Wang, Jie…[et al.]. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Journal of Diabetes Research No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1173254
American Medical Association (AMA)
Wang, Jie& Jin, Xinye& An, Ping& Yu, Songyan& Mu, Yi-Ming. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Journal of Diabetes Research. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1173254
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1173254